FGF23-Klotho signaling axis in the kidney

Bone

Volumn 100, Issue , 2017, Pages 62-68

  Erben, Reinhold G ^a   Andrukhova, Olena ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Calcium reabsorption; Fibroblast growth factor 23; Sodium reabsorption; Vitamin D metabolism phosphate transport

Indexed keywords

COLECALCIFEROL 24 HYDROXYLASE; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HYDROGEN SODIUM EXCHANGE REGULATORY COFACTOR 1; KLOTHO PROTEIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOTRANSFERASE; PROTEIN KINASE WNK4; SERUM GLUCOCORTICOID REGULATED KINASE 1; SODIUM CHLORIDE COTRANSPORTER; SODIUM PHOSPHATE COTRANSPORTER; UNCLASSIFIED DRUG; VITAMIN D; BETA GLUCURONIDASE; FIBROBLAST GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE;

BASOLATERAL MEMBRANE; CALCIUM ABSORPTION; CALCIUM TRANSPORT; COMPLEX FORMATION; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HORMONE SYNTHESIS; HUMAN; INTERNALIZATION; KIDNEY; KIDNEY DISTAL TUBULE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE EPITHELIUM; MOLECULAR DYNAMICS; NONHUMAN; PHOSPHATE TRANSPORT; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; SODIUM ABSORPTION; SODIUM TRANSPORT; ANIMAL; GENETICS; METABOLISM; PHYSIOLOGY;

ANIMALS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; SIGNAL TRANSDUCTION;

EID: 84994777630     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2016.09.010     Document Type: Review

References (81)

1. The ADHR Consortium, Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23. Nat. Genet. 26 (2000), 345–348.
2. Shimada, T., Mizutani, S., Muto, T., Yoneya, T., Hino, R., Takeda, S., Takeuchi, Y., Fujita, T., Fukumoto, S., Yamashita, T., Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 6500–6505.
3. Shimada, T., Hasegawa, H., Yamazaki, Y., Muto, T., Hino, R., Takeuchi, Y., Fujita, T., Nakahara, K., Fukumoto, S., Yamashita, T., FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19 (2004), 429–435.
4. Shimada, T., Yamazaki, Y., Takahashi, M., Hasegawa, H., Urakawa, I., Oshima, T., Ono, K., Kakitani, M., Tomizuka, K., Fujita, T., Fukumoto, S., Yamashita, T., Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am. J. Physiol. Ren. Physiol. 289 (2005), F1088–F1095.
5. Martin, A., David, V., Quarles, L.D., Regulation and function of the FGF23/klotho endocrine pathways. Physiol. Rev. 92 (2012), 131–155.
6. Clinkenbeard, E.L., Cass, T.A., Ni, P., Hum, J.M., Bellido, T., Allen, M.R., White, K.E., Conditional deletion of murine Fgf23: interruption of the normal skeletal responses to phosphate challenge and rescue of genetic hypophosphatemia. J. Bone Miner. Res., 2016.
7. Yoshiko, Y., Wang, H., Minamizaki, T., Ijuin, C., Yamamoto, R., Suemune, S., Kozai, K., Tanne, K., Aubin, J.E., Maeda, N., Mineralized tissue cells are a principal source of FGF23. Bone 40 (2007), 1565–1573.
8. Liu, S., Tang, W., Zhou, J., Vierthaler, L., Quarles, L.D., Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am. J. Physiol. Endocrinol. Metab. 293 (2007), E1636–E1644.
9. Juppner, H., Phosphate and FGF-23. Kidney Int. Suppl., 2011, S24–S27.
10. Kaneko, I., Saini, R.K., Griffin, K.P., Whitfield, G.K., Haussler, M.R., Jurutka, P.W., FGF23 gene regulation by 1,25-dihydroxyvitamin D: opposing effects in adipocytes and osteocytes. J. Endocrinol. 226 (2015), 155–166.
11. Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., Iwasaki, H., Iida, A., Shiraki-Iida, T., Nishikawa, S., Nagai, R., Nabeshima, Y.I., Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390 (1997), 45–51.
12. Xu, Y., Sun, Z., Molecular basis of Klotho: from gene to function in aging. Endocr. Rev. 36 (2015), 174–193.
13. Shiraki-Iida, T., Aizawa, H., Matsumura, Y., Sekine, S., Iida, A., Anazawa, H., Nagai, R., Kuro-o, M., Nabeshima, Y., Structure of the mouse klotho gene and its two transcripts encoding membrane and secreted protein. FEBS Lett. 424 (1998), 6–10.
14. Urakawa, I., Yamazaki, Y., Shimada, T., Iijima, K., Hasegawa, H., Okawa, K., Fujita, T., Fukumoto, S., Yamashita, T., Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444 (2006), 770–774.
15. Imura, A., Tsuji, Y., Murata, M., Maeda, R., Kubota, K., Iwano, A., Obuse, C., Togashi, K., Tominaga, M., Kita, N., Tomiyama, K., Iijima, J., Nabeshima, Y., Fujioka, M., Asato, R., Tanaka, S., Kojima, K., Ito, J., Nozaki, K., Hashimoto, N., Ito, T., Nishio, T., Uchiyama, T., Fujimori, T., Nabeshima, Y., alpha-Klotho as a regulator of calcium homeostasis. Science 316 (2007), 1615–1618.
16. Hu, M.C., Shi, M., Zhang, J., Pastor, J., Nakatani, T., Lanske, B., Razzaque, M.S., Rosenblatt, K.P., Baum, M.G., Kuro-o, M., Moe, O.W., Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J. 24 (2010), 3438–3450.
17. Andrukhova, O., Zeitz, U., Goetz, R., Mohammadi, M., Lanske, B., Erben, R.G., FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway. Bone 51 (2012), 621–628.
18. Lindberg, K., Amin, R., Moe, O.W., Hu, M.C., Erben, R.G., Ostman, W.A., Lanske, B., Olauson, H., Larsson, T.E., The kidney is the principal organ mediating klotho effects. J. Am. Soc. Nephrol. 25 (2014), 2169–2175.
19. Ornitz, D.M., Itoh, N., The fibroblast growth factor signaling pathway. Wiley Interdiscip. Rev. Dev. Biol., 2015.
20. Kurosu, H., Ogawa, Y., Miyoshi, M., Yamamoto, M., Nandi, A., Rosenblatt, K.P., Baum, M.G., Schiavi, S., Hu, M.C., Moe, O.W., Kuro, O., Regulation of fibroblast growth factor-23 signaling by Klotho. J. Biol. Chem. 281 (2006), 6120–6123.
21. Goetz, R., Ohnishi, M., Kir, S., Kurosu, H., Wang, L., Pastor, J., Ma, J., Gai, W., Kuro-o, M., Razzaque, M.S., Mohammadi, M., Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor. J. Biol. Chem. 287 (2012), 29134–29146.
22. Lederer, E., Renal phosphate transporters. Curr. Opin. Nephrol. Hypertens. 23 (2014), 502–506.
23. + exchanger regulatory factor-1 complexes. Am. J. Phys. Cell Physiol. 289 (2005), C159–C167.
24. Weinman, E.J., Biswas, R.S., Peng, G., Shen, L., Turner, C.L., X, E., Steplock, D., Shenolikar, S., Cunningham, R., Parathyroid hormone inhibits renal phosphate transport by phosphorylation of serine 77 of sodium-hydrogen exchanger regulatory factor-1. J. Clin. Invest. 117 (2007), 3412–3420.
25. Larsson, T., Marsell, R., Schipani, E., Ohlsson, C., Ljunggren, O., Tenenhouse, H.S., Juppner, H., Jonsson, K.B., Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145 (2004), 3087–3094.
26. Shimada, T., Urakawa, I., Yamazaki, Y., Hasegawa, H., Hino, R., Yoneya, T., Takeuchi, Y., Fujita, T., Fukumoto, S., Yamashita, T., FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem. Biophys. Res. Commun. 314 (2004), 409–414.
27. Li, S.A., Watanabe, M., Yamada, H., Nagai, A., Kinuta, M., Takei, K., Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct. Funct. 29 (2004), 91–99.
28. Farrow, E.G., Davis, S.I., Summers, L.J., White, K.E., Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J. Am. Soc. Nephrol. 20 (2009), 955–960.
29. Farrow, E.G., Summers, L.J., Schiavi, S.C., McCormick, J.A., Ellison, D.H., White, K.E., Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation. J. Endocrinol. 207 (2010), 67–75.
30. White, K.E., Econs, M.J., Fibroblast Growth Factor-23. Rosen, C.J., (eds.) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 2008, American Society of Bone and Mineral Research, Washington, DC, 112–116.
31. Weinman, E.J., Steplock, D., Shenolikar, S., Biswas, R., FGF-23-mediated inhibition of renal phosphate transport in mice requires NHERF-1 and synergizes with PTH. J. Biol. Chem. 286 (2011), 37216–37221.
32. Umbach, A.T., Zhang, B., Daniel, C., Fajol, A., Velic, A., Hosseinzadeh, Z., Bhavsar, S.K., Bock, C.T., Kandolf, R., Pichler, B.J., Amann, K.U., Foller, M., F., L., Janus kinase 3 regulates renal 25-hydroxyvitamin D 1alpha-hydroxylase expression, calcitriol formation, and phosphate metabolism. Kidney Int. 87 (2015), 728–737.
33. Gupta, A., Winer, K., Econs, M.J., Marx, S.J., Collins, M.T., FGF-23 is elevated by chronic hyperphosphatemia. J. Clin. Endocrinol. Metab. 89 (2004), 4489–4492.
34. Geller, J.L., Khosravi, A., Kelly, M.H., Riminucci, M., Adams, J.S., Collins, M.T., Cinacalcet in the management of tumor-induced osteomalacia. J. Bone Miner. Res. 22 (2007), 931–937.
35. Bhadada, S.K., Palnitkar, S., Qiu, S., Parikh, N., Talpos, G.B., Rao, S.D., Deliberate total parathyroidectomy: a potentially novel therapy for tumor-induced hypophosphatemic osteomalacia. J. Clin. Endocrinol. Metab. 98 (2013), 4273–4278.
36. Andrukhova, O., Streicher, C., Zeitz, U., Erben, R.G., Fgf23 and parathyroid hormone signaling interact in kidney and bone. Mol. Cell. Endocrinol. 436 (2016), 224–239.
37. Han, X., Yang, J., Li, L., Huang, J., King, G., Quarles, L.D., Conditional deletion of Fgfr1 in the proximal and distal tubule identifies distinct roles in phosphate and calcium transport. PLoS One, 11, 2016, e0147845.
38. Ide, N., Olauson, H., Sato, T., Densmore, M.J., Wang, H., Hanai, J., Larsson, T.E., Lanske, B., In vivo evidence for a limited role of proximal tubular Klotho in renal phosphate handling. Kidney Int. 90 (2016), 348–362.
39. Gattineni, J., Bates, C., Twombley, K., Dwarakanath, V., Robinson, M.L., Goetz, R., Mohammadi, M., Baum, M., FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am. J. Physiol. Ren. Physiol. 297 (2009), F282–F291.
40. Gattineni, J., Alphonse, P., Zhang, Q., Mathews, N., Bates, C.M., Baum, M., Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4. Am. J. Physiol. Ren. Physiol. 306 (2014), F351–F358.
41. Myakala, K., Motta, S., Murer, H., Wagner, C.A., Koesters, R., Biber, J., Hernando, N., Renal-specific and inducible depletion of NaPi-IIc/Slc34a3, the cotransporter mutated in HHRH, does not affect phosphate or calcium homeostasis in mice. Am. J. Physiol. Ren. Physiol. 306 (2014), F833–F843.
42. Bergwitz, C., Roslin, N.M., Tieder, M., Loredo-Osti, J.C., Bastepe, M., Abu-Zahra, H., Frappier, D., Burkett, K., Carpenter, T.O., Anderson, D., Garabedian, M., Sermet, I., Fujiwara, T.M., Morgan, K., Tenenhouse, H.S., Juppner, H., SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am. J. Hum. Genet. 78 (2006), 179–192.
43. Dinour, D., Davidovits, M., Ganon, L., Ruminska, J., Forster, I.C., Hernando, N., Eyal, E., Holtzman, E.J., Wagner, C.A., Loss of function of NaPiIIa causes nephrocalcinosis and possibly kidney insufficiency. Pediatr. Nephrol., 2016 (in press).
44. Fraser, D.R., Kodicek, E., Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature 228 (1970), 764–766.
45. Brunette, M.G., Chan, M., Ferriere, C., Roberts, K.D., Site of 1,25(OH)2 vitamin D3 synthesis in the kidney. Nature 276 (1978), 287–289.
46. Verstuyf, A., Carmeliet, G., Bouillon, R., Mathieu, C., Vitamin D: a pleiotropic hormone. Kidney Int. 78 (2010), 140–145.
47. Yoshida, T., Fujimori, T., Nabeshima, Y., Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. Endocrinology 143 (2002), 683–689.
48. Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., Yamashita, T., Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 113 (2004), 561–568.
49. Murali, S.K., Roschger, P., Zeitz, U., Klaushofer, K., Andrukhova, O., Erben, R.G., FGF23 regulates bone mineralization in a 1,25(OH) D and klotho-independent manner. J. Bone Miner. Res. 31 (2016), 129–142.
50. Sitara, D., Razzaque, M.S., Hesse, M., Yoganathan, S., Taguchi, T., Erben, R.G., Juppner, H., Lanske, B., Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 23 (2004), 421–432.
51. Ichikawa, S., Imel, E.A., Kreiter, M.L., Yu, X., Mackenzie, D.S., Sorenson, A.H., Goetz, R., Mohammadi, M., White, K.E., Econs, M.J., A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J. Clin. Invest. 117 (2007), 2684–2691.
52. Araya, K., Fukumoto, S., Backenroth, R., Takeuchi, Y., Nakayama, K., Ito, N., Yoshii, N., Yamazaki, Y., Yamashita, T., Silver, J., Igarashi, T., Fujita, T., A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J. Clin. Endocrinol. Metab. 90 (2005), 5523–5527.
53. Jones, G., Prosser, D.E., Kaufmann, M., 25-hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch. Biochem. Biophys. 523 (2012), 9–18.
54. Inoue, Y., Segawa, H., Kaneko, I., Yamanaka, S., Kusano, K., Kawakami, E., Furutani, J., Ito, M., Kuwahata, M., Saito, H., Fukushima, N., Kato, S., Kanayama, H.O., Miyamoto, K., Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem. J. 390 (2005), 325–331.
55. Perwad, F., Zhang, M.Y., Tenenhouse, H.S., Portale, A.A., Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am. J. Physiol. Ren. Physiol. 293 (2007), F1577–F1583.
56. Zhang, M.Y., Ranch, D., Pereira, R.C., Armbrecht, H.J., Portale, A.A., Perwad, F., Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice. Endocrinology 153 (2012), 1806–1816.
57. Ranch, D., Zhang, M.Y., Portale, A.A., Perwad, F., Fibroblast growth factor 23 regulates renal 1,25-dihydroxy vitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice. J. Bone Miner. Res. 26 (2011), 1883–1890.
58. Portale, A.A., Zhang, M.Y., David, V., Martin, A., Jiao, Y., Gu, W., Perwad, F., Characterization of FGF23-dependent egr-1 cistrome in the mouse renal proximal tubule. PLoS One, 10, 2015, e0142924.
59. Gattineni, J., Twombley, K., Goetz, R., Mohammadi, M., Baum, M., Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. Am. J. Physiol. Ren. Physiol., 2011.
60. Li, H., Martin, A., David, V., Quarles, L.D., Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype. Am. J. Physiol. Endocrinol. Metab. 300 (2011), E508–E517.
61. Andrukhova, O., Smorodchenko, A., Egerbacher, M., Streicher, C., Zeitz, U., Goetz, R., Shalhoub, V., Mohammadi, M., Pohl, E.E., Lanske, B., Erben, R.G., FGF23 promotes renal calcium reabsorption through the TRPV5 channel. EMBO J. 33 (2014), 229–246.
62. Andrukhova, O., Slavic, S., Smorodchenko, A., Zeitz, U., Shalhoub, V., Lanske, B., Pohl, E.E., Erben, R.G., FGF23 regulates renal sodium handling and blood pressure. EMBO Mol. Med. 6 (2014), 744–759.
63. 2 + handling. Kidney Int. 69 (2006), 650–654.
64. McCormick, J.A., Yang, C.L., Ellison, D.H., WNK kinases and renal sodium transport in health and disease: an integrated view. Hypertension 51 (2008), 588–596.
65. Jiang, Y., Ferguson, W.B., Peng, J.B., WNK4 enhances TRPV5-mediated calcium transport: potential role in hypercalciuria of familial hyperkalemic hypertension caused by gene mutation of WNK4. Am. J. Physiol. Ren. Physiol. 292 (2007), F545–F554.
66. Jiang, Y., Cong, P., Williams, S.R., Zhang, W., Na, T., Ma, H.P., Peng, J.B., WNK4 regulates the secretory pathway via which TRPV5 is targeted to the plasma membrane. Biochem. Biophys. Res. Commun. 375 (2008), 225–229.
67. Cha, S.K., Huang, C.L., WNK4 kinase stimulates caveola-mediated endocytosis of TRPV5 amplifying the dynamic range of regulation of the channel by protein kinase C. J. Biol. Chem. 285 (2010), 6604–6611.
68. Bazua-Valenti, S., Gamba, G., Revisiting the NaCl cotransporter regulation by with no-lysine kinases. Am. J. Phys. Cell Physiol. 308 (2015), C779–C791.
69. Chen, S.Y., Bhargava, A., Mastroberardino, L., Meijer, O.C., Wang, J., Buse, P., Firestone, G.L., Verrey, F., Pearce, D., Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 2514–2519.
70. Rozansky, D.J., Cornwall, T., Subramanya, A.R., Rogers, S., Yang, Y.F., David, L.L., Zhu, X., Yang, C.L., Ellison, D.H., Aldosterone mediates activation of the thiazide-sensitive Na-Cl cotransporter through an SGK1 and WNK4 signaling pathway. J. Clin. Invest. 119 (2009), 2601–2612.
71. van der Lubbe, N., Lim, C.H., Meima, M.E., Van, V.R., Rosenbaek, L.L., Mutig, K., Danser, A.H., Fenton, R.A., Zietse, R., Hoorn, E.J., Aldosterone does not require angiotensin II to activate NCC through a WNK4-SPAK-dependent pathway. Pflugers Arch. 463 (2012), 853–863.
72. Ko, B., Mistry, A.C., Hanson, L., Mallick, R., Wynne, B.M., Thai, T.L., Bailey, J.L., Klein, J.D., Hoover, R.S., Aldosterone acutely stimulates NCC activity via a SPAK-mediated pathway. Am. J. Physiol. Ren. Physiol. 305 (2013), F645–F652.
73. de Jong, M.A., Mirkovic, K., Mencke, R., Hoenderop, J.G., Bindels, R.J., Vervloet, M.G., Hillebrands, J.L., van den Born, J., Navis, G., de Borst, M.H., Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis. Nephrol. Dial. Transplant., 2016.
74. Scialla, J.J., Lau, W.L., Reilly, M.P., Isakova, T., Yang, H.Y., Crouthamel, M.H., Chavkin, N.W., Rahman, M., Wahl, P., Amaral, A.P., Hamano, T., Master, S.R., Nessel, L., Chai, B., Xie, D., Kallem, R.R., Chen, J., Lash, J.P., Kusek, J.W., Budoff, M.J., Giachelli, C.M., Wolf, M., Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int. 83 (2013), 1159–1168.
75. Dhingra, R., Sullivan, L.M., Fox, C.S., Wang, T.J., D'Agostino, R.B. Sr., Gaziano, J.M., Vasan, R.S., Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch. Intern. Med. 167 (2007), 879–885.
76. Di Lullo, L., Gorini, A., Bellasi, A., Morrone, L.F., Rivera, R., Russo, L., Santoboni, A., Russo, D., Fibroblast growth factor 23 and parathyroid hormone predict extent of aortic valve calcifications in patients with mild to moderate chronic kidney disease. Clin. Kidney J. 8 (2015), 732–736.
77. Nehgme, R., Fahey, J.T., Smith, C., Carpenter, T.O., Cardiovascular abnormalities in patients with X-linked hypophosphatemia. J. Clin. Endocrinol. Metab. 82 (1997), 2450–2454.
78. Lattanzio, M.R., Weir, M.R., Does blockade of the renin-angiotensin-aldosterone system slow progression of all forms of kidney disease?. Curr. Hypertens. Rep. 12 (2010), 369–377.
79. Juppner, H., Wolf, M., Salusky, I.B., FGF-23: More than a regulator of renal phosphate handling?. J. Bone Miner. Res. 25 (2010), 2091–2097.
80. Faul, C., Amaral, A.P., Oskouei, B., Hu, M.C., Sloan, A., Isakova, T., Gutierrez, O.M., Aguillon-Prada, R., Lincoln, J., Hare, J.M., Mundel, P., Morales, A., Scialla, J., Fischer, M., Soliman, E.Z., Chen, J., Go, A.S., Rosas, S.E., Nessel, L., Townsend, R.R., Feldman, H.I., St John, S.M., Ojo, A., Gadegbeku, C., Di Marco, G.S., Reuter, S., Kentrup, D., Tiemann, K., Brand, M., Hill, J.A., Moe, O.W., Kuro, O., Kusek, J.W., Keane, M.G., Wolf, M., FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121 (2011), 4393–4408.
81. Kovesdy, C.P., Quarles, L.D., FGF23 from bench to bedside. Am. J. Physiol. Ren. Physiol. 310 (2016), F1168–F1174.